real-world data

From the Field

Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer

05/19/2022

Junxin Shi , PhD;

Yiqiong Xie , PhD, MPH;

Katrine L. Wallace , PhD;

Robert Reid , MD;

Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.

Dr Wallace and colleagues...

05/19/2022

Journal of Clinical Pathways

Research Reports

Patterns and Predictors of Treatment Choice in a Real-World Cohort of Patients with Metastatic Gastric Cancer in the United States

09/22/2021

Sui Zhang , MS, MPP;

Astra M. Liepa , PharmD;

Lisa M. Hess , PhD;

Gary Meyer , PhD;

Thomas A. Abrams , MD;

Peter C. Enzinger , MD;

Jeffrey A. Meyerhardt , MD, MPH;

Charles S. Fuchs ;

Deborah Schrag , MD, MPH;

Yajun Zhu , MS;

Thomas A. Abrams, MD, and colleagues examine patterns of systemic therapy administration in metastatic gastric cancer and the predictors associated with specific treatment choices.

Thomas A. Abrams, MD, and...

09/22/2021

Journal of Clinical Pathways

Videos

Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma

03/12/2021

Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.

Nimira Alimohamed, MD, discusses...

03/12/2021

Journal of Clinical Pathways

News

Real-World Practice Patterns, Comorbidities in Medicare Patients With MCL

01/21/2021

Journal of Clinical Pathways

Conference Coverage

Weekly vs Biweekly Cetuximab for Metastatic Colorectal Cancer

01/19/2021

Journal of Clinical Pathways

News

Optimal Real-World Immunochemotherapy Regimen for Patients With MCL

06/25/2020

A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...

A...

06/25/2020

Journal of Clinical Pathways

News

Real-World HRU, Costs in Patients With MCL Treated With Drug Combo vs Chemoimmunotherapy

05/20/2020

Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...

...

05/20/2020

Journal of Clinical Pathways

Research in Review

Clinical Trial Efficacy Consistent with Real-World Outcomes, Study Shows

07/28/2017

JCP Editors

Researchers compared the relationship between randomized controlled clinical trial efficacy data and real-world effectiveness for oncology therapies, published in Value in Health (July-August,...

...

07/28/2017

Journal of Clinical Pathways

Real-World Data Shows Metastatic Bladder Cancer Survival Worse Than in Clinical Trials

05/31/2017

JCP Editors

Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research. Current overall survival projections for patients with...

Few...

05/31/2017

Journal of Clinical Pathways